Loading…
Hosted by Dr. Neil Love · 🇺🇸 US · EN · 61 episodes
Established thought leaders with verified media credentials.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
Dr. Neil Love hosts Lung Cancer Update, a science show with 61 episodes published.
Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Mainten
Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics: Introduction: Relative Impact of Targeted Treatment (00:00) HER2 Alterations (8:04) KRAS Mutations (24:25) MET Overexpre
Featuring perspectives from Dr Joshua K Sabari, including the following topics: Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00) Popat
Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics: Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line
Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treate
Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibo
Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targ
Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunother
Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications
Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCL
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer. CME information and select publications here.
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and sele
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publ
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publi
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publicati
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for pat
Jacob Sands
Dr. · Dana-Farber Cancer Institute
3 appearances on this show
Misty Dawn Shields
MD, PhD
1 appearance on this show
Jonathan Goldman
M.A. · CURA
1 appearance on this show
Christine L Hann
Johns Hopkins University School of Medicine
1 appearance on this show
Dr Natalie Vokes
The University of Texas MD Anderson Cancer Center
1 appearance on this show
Anne Chiang
Yale Cancer Center
1 appearance on this show
Hossein Borghaei
Fox Chase Cancer Center
1 appearance on this show
Dr Luis Paz-Ares
Spanish National Oncology Research Center
1 appearance on this show
Dr Shields
Indiana University School of Medicine
1 appearance on this show
Dr John V Heymach
The University of Texas MD Anderson Cancer Center
1 appearance on this show
Dr Aaron Lisberg
University of California, Los Angeles
2 appearances on this show
Dr Jacob Sands
Dana-Farber Cancer Institute
2 appearances on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Lung Cancer Update has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Lung Cancer Update is hosted by Dr. Neil Love. The show is categorised under science (health) and has published 61 episodes.
Lung Cancer Update has published 61 episodes.
Lung Cancer Update regularly covers science, health, fitness. It sits in the science category, with a health focus.
Lung Cancer Update is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Lung Cancer Update hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Lung Cancer Update average 54 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Lung Cancer Update's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.